BioSpace News Archive

Sientra, Inc., a medical aesthetics company uniquely focused on plastic surgeons, announced that on December 27, 2022, the Company approved equity award grants under the Sientra Inc. Inducement Plan to 13 new employees.

Viatris Inc., a global healthcare company, announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris’ newest members of its board of directors.

Evofem Biosciences, Inc. announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022.

Kane Biotech Inc. announces that it has reached an agreement to obtain loans in the aggregate amount of $2,000,000 from two lenders.

In 2022, Qilu Pharmaceutical revealed the latest progress being made with several clinical studies involving its innovative bifunctional antibody, QL1706, at several international and Chinese academic conferences, including the American Association for Cancer Research 2022 Annual Meeting, the American Society of Clinical Oncology 2022 Annual Meeting, the Chinese Society of Clinical Oncology 2022 Annual Meeting, and the European Society for Medical Oncology 2022 Asia Congress.

Acutus Medical, Inc. announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” for presentation during the Late-Breaking Clinical Trials and First Report Investigations session at the AF Symposium in Boston.

Ardelyx, Inc. announced that the Office of New Drugs, Center for Drug Evaluation and Research of the U.S. Food and Drug Administration granted the appeal to the Complete Response Letter for the New Drug Application for XPHOZAH.

Osteal Therapeutics, Inc. announced the expansion of its leadership team with the appointments of Kathy Burke as Vice President of Market Access, Clay Cohorn as Vice President of Clinical Affairs, Trey Putnam, PhD, RAC as Vice President of Regulatory Affairs and Quality Assurance, and Todd Saunders as Vice President of Marketing.

STEMCELL Technologies is proud to announce its President and CEO, Dr. Allen Eaves, has been appointed to the Order of Canada by Her Excellency the Right Honourable Mary Simon, the Governor General of Canada.

MediWound Ltd. announced that the U.S. Food and Drug Administration has approved NexoBrid® for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns.